Immunome Inc. — Investor Relations & Filings
Immunome Inc. is a clinical-stage oncology company focused on developing targeted therapies to improve outcomes for cancer patients. The company specializes in creating first-in-class and best-in-class therapeutic candidates, with a primary focus on Antibody-Drug Conjugates (ADCs) and Radioligand Therapies (RLTs). Immunome utilizes a systematic, data-driven process to optimize each component of its drug candidates—antibody, linker, and payload—to address high unmet medical needs. Its clinical pipeline includes varegacestat, a gamma secretase inhibitor in a Phase 3 trial for desmoid tumors; IM-1021, a ROR1-targeted ADC in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand. The company also advances a portfolio of preclinical ADCs targeting various solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| ARS - Immunome Inc. (0001472012) (Filer) | 2026-04-24 | English | |
| SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject) | 2026-03-26 | English | |
| 4 - Immunome Inc. (0001472012) (Issuer) | 2026-03-24 | English | |
| 144 - Immunome Inc. (0001472012) (Subject) | 2026-03-20 | English | |
| 10-K - IMMUNOME INC. (0001472012) (Filer) | 2026-03-03 | English | |
| 8-K - IMMUNOME INC. (0001472012) (Filer) | 2026-03-03 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 36260617 | ARS - Immunome Inc. (0001472012) (Filer) | 2026-04-24 | English | ||
| 33050365 | SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject) | 2026-03-26 | English | ||
| 33017259 | 4 - Immunome Inc. (0001472012) (Issuer) | 2026-03-24 | English | ||
| 33000829 | 144 - Immunome Inc. (0001472012) (Subject) | 2026-03-20 | English | ||
| 32892309 | 10-K - IMMUNOME INC. (0001472012) (Filer) | 2026-03-03 | English | ||
| 32892308 | 8-K - IMMUNOME INC. (0001472012) (Filer) | 2026-03-03 | English | ||
| 29982218 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
|
2025
8 filings
| |||||
| 12302604 | Director's Dealing 2025 | 2025-12-31 | English | ||
| 12302605 | Director's Dealing 2025 | 2025-12-23 | English | ||
| 12302609 | Major Shareholding Notification 2025 | 2025-12-23 | English | ||
| 12302606 | Director's Dealing 2025 | 2025-12-22 | English | ||
| 12302607 | Director's Dealing 2025 | 2025-12-22 | English | ||
| 12302608 | Director's Dealing 2025 | 2025-12-22 | English | ||
| 12302610 | Director's Dealing 2025 | 2025-12-18 | English | ||
| 12302611 | 8-K | 2025-12-17 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Coya Therapeutics, Inc.
Clinical-stage biotech developing therapies to enhance regu…
|
COYA | US | Manufacturing |
|
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Clinical-stage biotech firm focused on regenerative medicin…
|
CELZ | US | Manufacturing |
|
CRESCENT BIOPHARMA, INC.
Biopharmaceutical company researching and developing a pipe…
|
CBIO | US | Manufacturing |
|
Crescita Therapeutics Inc.
Commercial dermatology company developing and selling topic…
|
CTX | CA | Manufacturing |
|
Cresco Labs Inc.
Cultivates, manufactures, distributes, and sells medical an…
|
CRLBF | CA | Manufacturing |
|
Crinetics Pharmaceuticals, Inc.
Develops oral therapeutics for endocrine diseases and endoc…
|
CRNX | US | Manufacturing |
|
CRISM Therapeutics Corporation
Develops drug delivery technology for localized chemotherap…
|
CRTX | VG | Manufacturing |
|
CRISPR Therapeutics AG
A gene-editing company developing gene-based medicines for …
|
CRSP | CH | Manufacturing |
|
Crossject
Develops emergency medications delivered via a needle-free …
|
ALCJ | FR | Manufacturing |
|
CSL Ltd.
Global biotechnology company developing biotherapies, vacci…
|
CSL | AU | Manufacturing |
Immunome Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/32238/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=32238 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=32238 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=32238 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 32238}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Immunome Inc. (id: 32238)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.